About us
docturnal, established in April 2016, is a point of care screening & diagnostics solution for Lung health with a focus on Infectious diseases & lung cancer. Our flagship product TimBre™ – Is a solution for pulmonary TB screening and diagnostics. docturnal’s product portfolio also includes solutions for Pneumonia, COPD / Asthma with a pipeline of respiratory ailments (Lung Cancer) that can be identified with an acoustics component.
ACCURACY
SUCCESS-RATE
BETTER DATA
COST-EFFECTIVE
Meet Our Team
“It occurred to me by intuition, and music was the driving force behind that intuition. My discovery was the result of musical perception.”
Partnership with Molbio Diagnostics
This partnership shall pave way for using TimBre™ as a first line of defense followed by Truenat from Molbio to facilitate a robust TB screening & diagnostics strategy.
The collaboration has obtained test license from CDSCO, India & currently generating data for the marketing license purposes..
Partnership with big Pharma (undisclosed)
docturnal is actively partnering with global pharmaceutical companies to align TimBre™ with their respiratory product portfolio.
Support from USISTEF (Indo-US Endowment grant – 2024)
docturnal has received a grant from USISTEF to develop solutions for Lung Cancer screening and differentiating bacterial & viral Pneumonia cough signatures. TimBre™ is being repurposed to rollout these solutions during 2025
